Monday, 23 July 2018 - 12:41
  • it
  • de
  • en
  • fr

Zentiva

Advent offers €1.919bn for Sanofi’s Zentiva

Private equity Advent International has announced today in a press release that it is in exclusive talks with Sanofi to acquire Zentiva, the French company’s arm that markets generics all over Europe. Advent has offered Sanofi €1.919bn. Advent International, which…

Sanofi invests €350m on new vaccine production plant

France-based Sanofi has confirmed this week a significant €350m (CA$500m) investment to build a vaccine production plant in its plant in Toronto, Canada. The new investment makes the Canadian site one of the main plants of the group, with over…

Advent Capital now about to acquire Sanofi’s Zentiva ($2bn)

Advent International is reportedly about to acquire Zentiva, Sanofi’s European arm marketing generics. Advent has beaten its competitor, the investor BC Partners, the Financial Times has reported. Private equities Blackstone and Nordic Capital have already pulled out from the race…